Odilon Nouatin

Odilon Nouatin

Auto-generated profile, based on publicly available information

Odilon Nouatin

Clinical Research Institute of Benin , Abomey-Calavi 04 BP 1114, Cotonou , Benin

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
ONOdilon Nouatin
Odilon Nouatin
JMJuliana Boex Mengue
Juliana Boex Mengue
JAJean Claude Dejon Agobé
Jean Claude Dejon Agobé
RFRolf Fendel
Rolf Fendel
JIJavier Ibáñez
Javier Ibáñez
Ayola Akim ADEGNIKAAyola Akim ADEGNIKA
Ayola Akim ADEGNIKA
Background: Helminths can modulate the host immune response toPlasmodium falciparumand can therefore affect the risk of clinical malaria. We assessed here the effect of helminth infections on both the immunogenicity and efficacy of the GMZ2 malaria vaccine candidate, a recombinant protein consisting of conserved domains of GLURP and MSP3, two asexual blood-stage antigens ofP.falciparum. Controlled human malaria infection (CHMI) was used to assess the efficacy of the vaccine.Methodology: In a randomized, double-blind Phase I clinical trial, fifty, healthy, lifelong malaria-exposed adult volunteers received three doses of GMZ2 adjuvanted with either Cationic Adjuvant Formulation (CAF) 01 or Alhydrogel, or a control vaccine (Rabies) on days (D) 0, D28 and D56, followed by direct venous inoculation (DVI) of 3,200P.falciparumsporozoites (PfSPZ Challenge) approximately 13 weeks after last vaccination to assess vaccine efficacy. Participants were followed-up on a daily basis with clinical examinations and thick blood smears to monitorP.falciparumparasitemia for 35 days. Malaria was defined as the presence ofP.falciparumparasites in the blood associated with at least one symptom that can be associated to malaria over 35 days following DVI of PfSPZ Challenge. Soil-transmitted helminth (STH) infection was assessed by microscopy and by polymerase chain reaction (PCR) on stool, andSchistosomainfection was assessed by microscopy on urine. Participants were considered as infected if positive for any helminth either by PCR and/or microscopy at D0 and/or at D84 (Helm+) and were classified as mono-infection or co-infection. Total vaccine-specific IgG concentrations assessed on D84 were analysed as immunogenicity outcome.Main findings: The helminth in mono-infection, particularlySchistosoma haematobiumand STH were significantly associated with earlier malaria episodes following CHMI, while no association was found in case of coinfection. In further analyses, the anti-GMZ2 IgG concentration on D84 was significantly higher in theS.haematobium-infected and significantly lower in theStrongyloides stercoralis-infected groups, compared to helminth-negative volunteers. Interesting, in the absence of helminth infection, a high anti-GMZ2 IgG concentration on D84 was significantly associated with protection against malaria.Conclusions: Our results suggest that helminth infection may reduce naturally acquired and vaccine-induced protection against malaria. Vaccine-specific antibody concentrations on D84 may be associated with protection in participants with no helminth infection. These results suggest that helminth infection affect malaria vaccine immunogenicity and efficacy in helminth endemic countries.

5 February 2020 in Parasite Immunology
Verified
Journal Article
Closed access
PDF file
LTLéonidas Tokplonou
Léonidas Tokplonou
ONOdilon Nouatin
Odilon Nouatin
PSPaulin Sonon
Paulin Sonon
GMGrace M’pO
Grace M’pO
SGSonya Glitho
Sonya Glitho
DCDavid Courtin
David Courtin

5 May 2020 in Vaccine
Verified
Journal Article
Closed access
ONOdilon Nouatin
Odilon Nouatin
UNUlysse Ateba Ngoa
Ulysse Ateba Ngoa
JIJavier Ibáñez
Javier Ibáñez
JAJean Claude Dejon Agobé
Jean Claude Dejon Agobé
BMBenjamin Mordmüller
Benjamin Mordmüller
Ayola Akim ADEGNIKAAyola Akim ADEGNIKA
Ayola Akim ADEGNIKA

27 September 2024 in Infection, Genetics and Evolution
Verified
Journal Article
Open access
AYAnges Yadouleton
Anges Yadouleton
ONOdilon Nouatin
Odilon Nouatin
IKIslamiath Kissira
Islamiath Kissira
PHParfait Houngbegnon
Parfait Houngbegnon
GCGilles Cottrell
Gilles Cottrell
AMAchille Massougbodji
Achille Massougbodji
Dengue is a widespread viral infection transmitted from mosquitoes to humans, mainly in tropical and subtropical climates. In Benin, only dengue virus (DENV) serotype 2 infection has been previously described in humans. This study aimed to investigate DENV infection and serotypes in suspected patients. Plasma samples from 464 patients attending health centers in February 2023 with clinical symptoms and suspected for dengue infection were included, and analyzed for DENV by real time quantitative Polymerase Chain Reaction (Dengue Altona 3.0 kit). PCR positives samples were further characterized by whole genome sequencing and phylogenetic analysis to identify the circulating DENV serotype. The RT-qPCR results showed that four patients (D6, D23, D28, D44) were positive with the cycle threshold values less than 40 (31.3, 34.7, 14.7 and 14.3) respectively. Full-length DENV sequences were obtained for D6, D28 and D44. One patient (D6) was infected with DENV-1 serotype, and the two others (D28 and D44) were positive for DENV-3. Phylogenetic analysis shows that the new DENV-1 sequence is close to those obtained in Burkina Faso in 2022 and Nigeria in 2023, and the two DENV-3 sequences form a separate cluster with sequences obtained in Burkina Faso in 2022. We showed for the first time, the presence of dengue serotype 1 and serotype 3 infection in Benin. These results send a strong signal to health authorities and show that arbovirus surveillance efforts must be integrated into pathogen monitoring programs.

17 June 2022 in Malaria Journal
Verified
Journal Article
Open access
PDF file
ONOdilon Nouatin
Odilon Nouatin
JIJavier Ibáñez
Javier Ibáñez
RFRolf Fendel
Rolf Fendel
UNUlysse A. Ngoa
Ulysse A. Ngoa
FLFreia-Raphaella Lorenz
Freia-Raphaella Lorenz
BMBenjamin Mordmüller
Benjamin Mordmüller
Background: Antibody and cellular memory responses following vaccination are important measures of immunogenicity. These immune markers were quantified in the framework of a vaccine trial investigating the malaria vaccine candidate GMZ2. Methods: Fifty Gabonese adults were vaccinated with two formulations (aluminum Alhydrogel and CAF01) of GMZ2 or a control vaccine (Verorab). Vaccine efficacy was assessed using controlled human malaria infection (CHMI) by direct venous inoculation of 3200 live Plasmodium falciparum sporozoites (PfSPZ Challenge). GMZ2-stimulated T and specific B-cell responses were estimated by flow cytometry before and after vaccination. Additionally, the antibody response against 212 P. falciparum antigens was estimated before CHMI by protein microarray. Results: Frequencies of pro- and anti-inflammatory CD4+ T cells stimulated with the vaccine antigen GMZ2 as well as B cell profiles did not change after vaccination. IL-10-producing CD4+ T cells and CD20+ IgG+ B cells were increased post-vaccination regardless of the intervention, thus could not be specifically attributed to any malaria vaccine regimen. In contrast, GMZ2-specific antibody response increased after the vaccination, but was not correlated to protection. Antibody responses to several P. falciparum blood and liver stage antigens (MSP1, MSP4, MSP8, PfEMP1, STARP) as well as the breadth of the malaria-specific antibody response were significantly higher in protected study participants. Conclusions: In lifelong malaria exposed adults, the main marker of protection against CHMI is a broad antibody pattern recognizing multiple stages of the plasmodial life cycle. Despite vaccination with GMZ2 using a novel formulation, expansion of the GMZ2-stimulated T cells or the GMZ2-specific B cell response was limited, and the vaccine response could not be identified as a marker of protection against malaria. Trial registration PACTR; PACTR201503001038304; Registered 17 February 2015; https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=1038

1 January 2026 in AIDS Research and Treatment
Verified
Journal Article
Open access
PDF file
YAYaou Pierrot Assogba
Yaou Pierrot Assogba
ONOdilon Paterne Nouatin
Odilon Paterne Nouatin
ETEdmond Tchiakpe
Edmond Tchiakpe
AAAdefounke Prudencia Adechina
Adefounke Prudencia Adechina
RFRufine Abossèdé Fachinan
Rufine Abossèdé Fachinan
AYAkadiri Yessoufou
Akadiri Yessoufou
Until now, human immunodeficiency virus type 1 infection monitoring is based on plasma viral load and cluster of differentiation (CD)4–positive cells from thymus (CD4+ T cells) count. However, it is increasingly accepted that this biological monitoring should be strengthened with other markers that would reinforce the management. Therefore, we addressed this task by assessing the risk associated with therapeutic failure/success linked to the dynamic of immunological parameters in people living with HIV‐1 (PLHIV‐1) and on antiretroviral therapy (ART) in order to identify their prognostic values. Ninety enrolled PLHIV‐1 were classified according to their therapeutic status. Twenty healthy persons were also recruited as a control group. Serum cytokine levels and immune cell frequencies were determined, and the risk of therapeutic failure associated with immunological parameters was assessed. We observed low frequencies of CD4+ T, natural killer (NK), natural killer T (NKT) cells, classical monocytes, nonclassical monocytes, granulocytes, and high frequency of CD8+ T cells in all PLHIV‐1 groups in treatment failure under dolutegravir (DTG) and efavirenz (EFV) regimens compared to control participants. Moreover, interferon‐gamma (IFN‐γ) levels decreased in PLHIV‐1 with therapeutic success under the DTG regimen, while interleukin‐4 (IL‐4) increased in treatment success under the EFV regimen. Proinflammatory tumor necrosis factor‐alpha (TNF‐α), IL‐6, and IL‐7 significantly increased in therapeutic failure groups under both regimens. IL‐5 concentrations increased in all PLHIV‐1, while IL‐13 levels did not change. Logistic regression analysis revealed a positive correlation between the risk of treatment failure and proinflammatory cytokines IFN‐γ, TNF‐α, IL‐6, IL‐7, eosinophils, and CD8+ T cells in PLHIV‐1 under EFV and DTG regimes. In contrast, the risk of therapeutic failure decreased with increasing numbers of CD4+ T cells, neutrophils, and the anti‐inflammatory IL‐4 in PLHIV‐1 treated with the same antiretroviral molecules. Collectively, these results indicated that pro‐ and anti‐inflammatory cytokines and immune cells could serve as prognostic factors for monitoring HIV‐1 disease progression and response to ART. However, further studies with a larger sample size would be needed to confirm our data.